Source Bioscience Share Discussion Threads

[buywell2] 08/4/2016 07:33

POST REMOVED

[buywell3] 07/4/2016 15:10

Your point is noted

However many of these fatties, shall we say , as we are not splitting hairs here , go on to develop diabetes , plus a variety of other cardiovascular,heart related issues, strokes and cancers.

The majority of the NHS budget will be spent on health issues as a result of being fat/having diabetes.

I would not be surprised if in fact that number was not over 50% as I key.

My point is we screen everyone for diabetes PLUS we weigh them

If they are obese ... they have to have a band fitted or diet ... they enter a program

If over the next 6 months they have not lost 10% of their body mass

1. Those on benefits get a 10% reduction ( as they can afford to eat/drink too much)

2. Those not on benefits , have to start paying for their NHS treatments till they get their weight into program guidelines.



Drastic action is needed NOT the gentle hand that currently exists as it is costing those who are slim enough to work their future as the self inflicted poor health of the porkies drags the NHS into bankruptcy and kills it off.

[iconoclast] 07/4/2016 12:31

Well I must say I agree with the NSC recommendations.
It's hard to see how screening would make any difference to the health of the nation.
It is evident that despite the observable overweight, obesity and generally poor health suffered by such a large percentage of the population addicted to fast food, sugar high drinks and indolence; Advertising campaigns, obesity clinic programs on television, high statistical health damage etcetera, have no effect on the behaviour of the sufferers.
Worse still, we have a taboo strongly in place of even mentioning that people are fat or obese and if you were to attempt to mention this you will be accused of discrimination or fat phobia.
I see no reason to waste NHS funds on more evidence of the self indulgent problem.

[buywell2] 07/4/2016 06:44

POST REMOVED

[buywell3] 05/4/2016 07:24

The share price is now sitting on its 300 Day average




I would suggest that the BOD gets its finger out and gives us some good news before it goes through it

An increase in turnover of 4% has not impressed the market despite the 40% rise in profits to £2 Million

[buywell2] 01/4/2016 20:22

POST REMOVED

[buywell2] 27/3/2016 10:17

POST REMOVED

[buywell2] 26/3/2016 10:26

POST REMOVED

[buywell3] 23/3/2016 07:18

The numbers below are based roughly upon 15% growth in turnover

Which I have used before myself

However

I expect and hope that the SBS BOD can do better by acquiring another company this year ... one that is either cash generative or about to be within 12 months

And another in 2017 and another in 2018

Their track record to date has been good in doing such acquisitions


These NEW acquisitions will mean turnover/profit numbers will then be higher as cross selling opportunities arise and cost savings materialize across the SourceBiosSience Group ....

Thus leading to higher and higher margins

I expect the BOD to have a target of taking the existing margin from 50% where it now sits to 55% by 2018


Cyprotex (CRX) soon to report their finals will have a margin of over 75%






What the Nomad says as of today WITHOUT the acquisitions mentioned above





Broker N&1Singer forecasts revenue to move to £30.5m this year to £35m by 2018, with non adjusted pre-tax profits going to a 2016 £3.5m, on to £4.1m next year with £4.9m the following year.

Also worthy of note is the expectation on the reduction of debt which is anticipated moving down to £500k by this year end into a net cash position of £8.6m by 2018.

Looking purely at the forward PER of 21 on the non adjusted figures the shares may not look so cheap. However, taking other factors into consideration including a generating of cash aligned to a growth sector, then SBS shares may well be attractive at these levels.

On the adjusted numbers, which so many companies appear to prefer to use, pre-tax profits for this year come out at a forecast £4.4m with EPS of 1p giving a PER of 15 falling to 13 next year.

[hastings] 22/3/2016 16:42

Results were very good imo, added a few thoughts that may be of interest to some holders or those taking a look.

[bartdude] 22/3/2016 10:22

Very positive results and for the future growth of SBS shareprice

[buywell3] 22/3/2016 08:05

The acquisition of Select Pharma was made in August 2015


So it did not add much to the 2015 SBS final results

In 2016 it will , both in its own right with its existing clients and by cross selling to new clients from the SBS client list.


Thus I am expecting a rise in turnover of around £ 5M in 2016 from this acquisition with a rise in profits of £0.75M


Can we have another please ?





Outlook

We believe that the Group has a very strong business model and opportunities for further growth are apparent across the Laboratory Services and Products divisions. The Board's strategy is to expand the service and product offering, enabling greater market penetration, with the objective of delivering increasing value for shareholders. The aim is to achieve this through continued organic growth from the enlarged infrastructure in addition to further, carefully selected acquisitions when the opportunities arise, building on the strong foundations now established in the business.

[buywell3] 22/3/2016 07:32

22/03/2016 07:00 UKREG Source BioScience PLC Final Results


Financial performance

Group revenue increased to GBP26.3 million (2014: GBP25.2 million). Whilst the UK remains the largest market for the Group, strategies to increase the penetration of overseas markets are starting to gain traction. During the year, sales to non-UK customers increased by 19% to GBP6.0 million (2014: GBP5.0 million) with European customers representing the greatest element of the increase.

Gross margin improved to 50% (2014: 48%), generated from the operational gearing inherent within the laboratory and production infrastructure, coupled with close management of the cost base. In the current economic environment with constant pressure on prices and rising input costs, the Board believes this represents a solid performance.

Normal administrative expenses were broadly consistent as a percentage of revenue at 26% (2014: 25%), the slight increase representing the additional cost base acquired with Select and the additional investment in marketing and other commercial activities. Ongoing administrative expenses are largely fixed and appropriate to the increasing scale of the business.

On a reported basis, the operating profit for the year was GBP2.3 million (2014: GBP1.8 million profit), an increase of 29%.

Adjusted* profit before tax was GBP3.3 million (2014: GBP2.8 million). This was in line with expectations before recognising the additional GBP0.4 million share-based payment charge in the year, following the approval of the Company's new Long-Term Incentive Plan at the Annual General Meeting in June 2015.

Included in the Consolidated Statement of Comprehensive Income are non-cash items, including depreciation, amortisation and share-based payment costs of GBP2.8 million (2014: GBP2.5 million). After adjusting for these non-cash items, non-recurring acquisition and restructuring costs, net finance expense and taxation, adjusted* EBITDA increased by 13% to GBP5.8 million (2014: GBP5.1 million).

Financial position

At 31 December 2015 the Group had net assets of GBP31.8 million (2014: GBP25.4 million). Non-current assets increased by a net GBP7.5 million to GBP37.1 million (2014: GBP29.6 million). The movement included GBP6.9 million of goodwill and GBP1.4 million of intangible assets arising from the acquisitions, in addition to GBP1.7 million of capital expenditure offset by an aggregate GBP2.4 million of depreciation and amortisation.

At 31 December 2015 the Group had gross debt of GBP8.1 million (2014: GBP6.9 million), being the bank lending secured to part-fund the acquisitions in 2013 and 2015. The outstanding balance has been reduced during the year by scheduled repayments totalling GBP2.2 million. Net debt was GBP3.8 million (2014: GBP4.3 million).

[buywell3] 22/3/2016 07:14

22/03/2016 07:00 UKREG Source BioScience PLC Final Results

[buywell2] 21/3/2016 08:44

POST REMOVED

[buywell2] 16/3/2016 22:41

POST REMOVED

[wilkie_hk] 16/3/2016 11:10

Well, digitalook is publishing the predictions as per below, with a bottom line of £3.18M and EPS growth of 33%. If we achieve this and the forward statement indicates that we are still growing revenues and can achieve the forecast 28% for next year, then these will be good value after the recent slippage. However, the sellers are not convinced. Hopefully, the sellers' worries can be proved to be unfounded.

Year Ending/Revenue (£m)/Pre-tax (£m)/EPS/P-E/PEG/EPS Grth./Div/Yield

2015-12-31 26.33 3.18 0.74p 20.5 0.6 33% 0.00p 0.0%
2016-12-31 30.19 4.33 0.95p 16.1 0.6 28% 0.00p 0.0%
2017-12-31 32.22 4.87 1.07p 14.3 1.1 13% 0.00p 0.0%

[buywell2] 11/3/2016 00:10

POST REMOVED

[buywell2] 11/3/2016 00:02

POST REMOVED

[buywell2] 08/3/2016 21:41

One would have thought the BOD might release results a bit sooner

Profits of circa 3M should keep most happy I would have thought

[peterz] 07/3/2016 17:30

Blimey a bit of slippage going on - anyone know why??

[buywell2] 04/2/2016 23:18

Biotech and pharmaceutical companies pursue targeted and specialized therapies.

Companies have also invested millions in new treatments known as precision or personalized medicine that rely on advances in genomics and big data to target very specific types of cancer or other diseases affecting small groups of patients. For example, a drug called Herceptin, approved in 2006, treats women whose breast cancer has too many copies of a specific gene that manufactures a protein that can stimulate out-of-control cell growth.

PricewaterhouseCoopers notes that 94 percent of companies are invested in research related to personalized medicine, and the Personalized Medicine Coalition says 20 percent of new drug approvals in 2014 went to these treatments. "That's one of the pillars where we believe growth will come from," Reh said.

[buywell2] 01/2/2016 22:14

I expect profits to come in at around 3M GDP

As Select Pharma adds to turnover in 2016 , Interims should impress V those of 2015.

Clearly another acquisition is required to make up for the fall off of the cervical cancer smear testing.

I hope to see further cash raised at perhaps 17p to fund such.

I would like to see SBS get involved with providing the Food Industry with DNA and Bacteria testing by acquiring a company that already does with contracts with one or more of the BIG 6 Supermarkets in place.

Circa 10m to 12m will be needed for such.